Bristol Myers Squibb (BMY) Projected to Post Quarterly Earnings on Thursday

Bristol Myers Squibb (NYSE:BMY) is expected to announce its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect Bristol Myers Squibb to post earnings of $1.65 per share and revenue of $11.7541 billion for the quarter. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS.Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:00 AM ET.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.07 by $0.39. The business had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.07 EPS. On average, analysts expect Bristol Myers Squibb to post $7 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Bristol Myers Squibb Stock Performance

BMY opened at $42.82 on Wednesday. The firm has a market capitalization of $87.16 billion, a P/E ratio of 17.27, a price-to-earnings-growth ratio of 2.27 and a beta of 0.33. The stock’s 50 day moving average price is $45.54 and its two-hundred day moving average price is $46.92. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb has a 12-month low of $42.75 and a 12-month high of $63.33.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be issued a $0.62 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.8%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 100.00%.

Insider Activity at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the sale, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.07% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of institutional investors have recently made changes to their positions in the stock. Man Group plc grew its stake in shares of Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after purchasing an additional 5,503,391 shares during the period. California State Teachers Retirement System lifted its holdings in shares of Bristol Myers Squibb by 2.1% in the second quarter. California State Teachers Retirement System now owns 3,401,880 shares of the biopharmaceutical company’s stock valued at $157,473,000 after purchasing an additional 71,029 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Bristol Myers Squibb by 5.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 3,298,880 shares of the biopharmaceutical company’s stock valued at $152,932,000 after purchasing an additional 156,658 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Bristol Myers Squibb by 0.8% in the second quarter. The Manufacturers Life Insurance Company now owns 1,485,016 shares of the biopharmaceutical company’s stock valued at $68,741,000 after purchasing an additional 11,416 shares in the last quarter. Finally, Treasurer of the State of North Carolina lifted its holdings in shares of Bristol Myers Squibb by 2.5% in the second quarter. Treasurer of the State of North Carolina now owns 952,013 shares of the biopharmaceutical company’s stock valued at $44,069,000 after purchasing an additional 23,364 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have commented on the company. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Daiwa America downgraded Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Finally, Daiwa Capital Markets downgraded Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price for the company. in a research report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fourteen have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $57.23.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.